MA53119B1 - Formulation thermostable d'insuline humaine a21g - Google Patents

Formulation thermostable d'insuline humaine a21g

Info

Publication number
MA53119B1
MA53119B1 MA53119A MA53119A MA53119B1 MA 53119 B1 MA53119 B1 MA 53119B1 MA 53119 A MA53119 A MA 53119A MA 53119 A MA53119 A MA 53119A MA 53119 B1 MA53119 B1 MA 53119B1
Authority
MA
Morocco
Prior art keywords
human insulin
thermostable
formulation
thermostable formulation
composition
Prior art date
Application number
MA53119A
Other languages
English (en)
Other versions
MA53119A (fr
Inventor
You-Ping Chan
Lorenzo Fany Di
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adocia filed Critical Adocia
Publication of MA53119A publication Critical patent/MA53119A/fr
Publication of MA53119B1 publication Critical patent/MA53119B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition sous forme d'une solution aqueuse injectable, dont le ph est compris entre 7,2 et 8,0 (7,2 < ph < 8,0) comprenant au moins de l'insuline humaine a21g, ladite composition étant destinée à être utilisée dans une méthode de traitement du diabète caractérisée en ce qu'elle est administrée en bolus avant les repas.
MA53119A 2018-07-13 2019-07-15 Formulation thermostable d'insuline humaine a21g MA53119B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1856479A FR3083700B1 (fr) 2018-07-13 2018-07-13 Formulation thermostable d'insuline humaine a21g
PCT/EP2019/069049 WO2020012040A1 (fr) 2018-07-13 2019-07-15 Formulation thermostable d'insuline humaine a21g

Publications (2)

Publication Number Publication Date
MA53119A MA53119A (fr) 2021-05-19
MA53119B1 true MA53119B1 (fr) 2022-12-30

Family

ID=65200906

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53119A MA53119B1 (fr) 2018-07-13 2019-07-15 Formulation thermostable d'insuline humaine a21g

Country Status (6)

Country Link
US (1) US20210315977A1 (fr)
EP (1) EP3820501B1 (fr)
CN (1) CN112584854A (fr)
FR (1) FR3083700B1 (fr)
MA (1) MA53119B1 (fr)
WO (1) WO2020012040A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023020961A2 (pt) 2021-04-11 2023-12-12 Elgan Pharma Ltd Formulações de insulina e métodos para usar a mesma em bebês prematuros

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4750643A1 (es) * 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1076066A1 (fr) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
CN101060856B (zh) * 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
EP2241327A1 (fr) * 2006-03-15 2010-10-20 Novo Nordisk A/S Melange d'amyline et d'insuline
WO2007135118A1 (fr) * 2006-05-24 2007-11-29 Novo Nordisk A/S Formules solubles stables contenant de l'insuline
EP2178911A2 (fr) * 2007-08-13 2010-04-28 Novo Nordisk A/S Analogues de l'insuline à action rapide
ES2558930T3 (es) * 2007-08-13 2016-02-09 Novo Nordisk A/S Análogos de la insulina de acción rápida
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
DK2741765T3 (en) * 2011-08-10 2016-06-13 Adocia Injectable solution of at least one type of basal insulin
TW201605489A (zh) * 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
WO2017032797A1 (fr) * 2015-08-25 2017-03-02 Novo Nordisk A/S Nouveaux dérivés de l'insuline et leurs utilisations médicales
EP3393497A1 (fr) * 2015-12-23 2018-10-31 Sanofi-Aventis Deutschland GmbH Effet métabolique cardiaque du lantus

Also Published As

Publication number Publication date
US20210315977A1 (en) 2021-10-14
FR3083700A1 (fr) 2020-01-17
EP3820501A1 (fr) 2021-05-19
MA53119A (fr) 2021-05-19
EP3820501B1 (fr) 2022-09-14
FR3083700B1 (fr) 2021-03-12
WO2020012040A1 (fr) 2020-01-16
CN112584854A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
AR105712A1 (es) Composiciones de insulina de rápida acción
EA201792559A1 (ru) Фармацевтические композиции для местного применения
BR112017019515A2 (pt) análogo de insulina, composição farmacêutica e método de tratamento de um paciente
AR109494A1 (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
MA40709A1 (fr) Dérivé du glucagon à stabilité améliorée
EA201070121A1 (ru) Лекарственная форма, содержащая слитый белок glp-1-fc
MA49678A (fr) Compositions sous forme d&#39;une solution aqueuse injectable comprenant au moins l&#39;insuline humaine a21g et un suppresseur de glucagon a action prandiale
PA8782201A1 (es) Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos
BR112014010275A2 (pt) formulações para tratamento de diabetes
FR3059666B1 (fr) Procede de preparation de microcapsules de taille controlee comprenant une etape de photopolymerisation.
PE20191836A1 (es) Compuesto de insulina acilada
MA53119B1 (fr) Formulation thermostable d&#39;insuline humaine a21g
FR3032883B1 (fr) Composition pour la prevention et le traitement de la steatose et de la steatohepatite metaboliques
EA201691420A1 (ru) Композиции енолазы 1 (eno1) и их применение
EA201491369A1 (ru) Способ лечения сахарного диабета при помощи негликозилированного аполипопротеина a-iv
FR3020952B1 (fr) Formulation a action rapide d&#39;insuline comprenant un compose anionique substitue et un compose polyanionique
FR3084584B1 (fr) Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
PE20200402A1 (es) Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4de lipoxina (fpr2/alx) para el tratamiento de la insuficiencia cardiaca
EA201992685A1 (ru) Раствор леводопы для инфузий
MA45890B2 (fr) Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
MA54276B1 (fr) Montélukast destinée au traitement de l&#39;arthrose de la main
MA49396B1 (fr) Traitement de la migraine avec acétyl-leucine
CL2021000892A1 (es) Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica
MA43352A (fr) Protéine sans phénylalanine pour le traitement de la phénylcétonurie
FR3056908B1 (fr) Sel de metformine et d&#39;elafibranor presentant une activite duale pour le traitement de l&#39;obesite associee a la steato-hepatite non alcoolique (nash) et a l&#39;hypertriglyceridemie